Efficacy and Safety of Combined Brain Stereotactic Radiotherapy and Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with Brain Metastases

Bibliographic Details
Title: Efficacy and Safety of Combined Brain Stereotactic Radiotherapy and Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with Brain Metastases
Authors: Judith Porte, Caroline Saint-Martin, Thomas Frederic-Moreau, Marie-Ange Massiani, Laurence Bozec, Kim Cao, Pierre Verrelle, Joelle Otz, Eric Jadaud, Mathieu Minsat, Adriana Langer, Nicolas Girard, Gilles Créhange, Arnaud Beddok
Source: Biomedicines, Vol 10, Iss 9, p 2249 (2022)
Publisher Information: MDPI AG, 2022.
Publication Year: 2022
Collection: LCC:Biology (General)
Subject Terms: stereotactic radiotherapy, immunotherapy, non-small cell lung cancer, brain metastases, Biology (General), QH301-705.5
More Details: Background: To analyze the outcomes of patients with brain metastases (BM) from non-small cell lung cancer (NSCLC) treated with immunotherapy (IT) and stereotactic radiotherapy (SRT) and to study the impact of the sequence between the two modalities. Methods: The authors reviewed the records of 51 patients with 84 BM from NSCLC treated at Institut Curie with IT and SRT. BM were categorized into three groups: ‘SRT before IT’, ‘concurrent SRT and IT’, and ‘SRT after IT.’ Regional progression-free interval (R-PFI) and overall survival (OS) were estimated using the Kaplan–Meier method. Results: After a median follow-up from SRT of 22.5 months (2.7–47.3), the 1-year and 2-year OS were 69.7% (95%CI [58.0–83.8]) and 44.0% [30.6–63.2], respectively. Concerning distant intracranial control, the 1-year and 2-year R-PFI were 40.1% [30.1–53.3] and 35.2% [25.1–49.4], respectively. Moreover, one-year R-PFI in ‘SRT before IT’, ‘concurrent SRT and IT’, and ‘SRT after IT’ groups were 24.1%, 49.6%, and 34.2%, respectively (p = 0.094). The type of therapeutic sequence did not appear to impact the risk of brain necrosis. Conclusions: The concurrent administration of SRT and IT appeared to offer the best locoregional control, without increasing the risk of toxicity, compared to patients treated with SRT before or after IT.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2227-9059
Relation: https://www.mdpi.com/2227-9059/10/9/2249; https://doaj.org/toc/2227-9059
DOI: 10.3390/biomedicines10092249
Access URL: https://doaj.org/article/97260f821219478d9957fa41ab8b6872
Accession Number: edsdoj.97260f821219478d9957fa41ab8b6872
Database: Directory of Open Access Journals
More Details
ISSN:22279059
DOI:10.3390/biomedicines10092249
Published in:Biomedicines
Language:English